Cleared Traditional

CAVERMAP SURGICAL AID (K041732) - FDA 510(k) Clearance

Class I Gastroenterology & Urology device.

K041732 · Blue Torch Medical Technologies · Gastroenterology & Urology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Sep 2004
Decision
88d
Days
Class 1
Risk

K041732 is an FDA 510(k) clearance for the CAVERMAP SURGICAL AID. Classified as Probe And Director, Gastro-urology (product code FGM), Class I - General Controls.

Submitted by Blue Torch Medical Technologies (Ashland, US). The FDA issued a Cleared decision on September 21, 2004 after a review of 88 days - a notably fast clearance cycle.

This device falls under the Gastroenterology & Urology FDA review panel, regulated under 21 CFR 876.4730 - the FDA gastroenterology and urology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Blue Torch Medical Technologies devices

Submission Details

510(k) Number K041732 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received June 25, 2004
Decision Date September 21, 2004
Days to Decision 88 days
Submission Type Traditional
Review Panel Gastroenterology & Urology (GU)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
42d faster than avg
Panel avg: 130d · This submission: 88d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code FGM Probe And Director, Gastro-urology
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 876.4730
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.